Results
Thirty-six English-language and eight non-English-language studies were included in the review. Most of these studies involved
upper-limb lymphedema secondary to breast cancer. Despite lymphedema's
chronicity, lengths of
follow-up in most studies were under six months. Many trial reports contained inadequate descriptions of randomization, blinding, and methods to assess harms. Most observational studies did not control for confounding. Many studies showed that active treatments reduced the size of lymphatic limbs, although extensive between-study heterogeneity in areas such as treatment comparisons and protocols, and outcome measures, prevented us from assessing whether any one treatment was superior. This heterogeneity also precluded us from statistically pooling results. Harms were rare (<1% incidence) and mostly minor (e.g., headache, arm pain).
Conclusions
The literature contains no evidence to suggest the most effective treatment for secondary lymphedema. Harms are few and unlikely to cause major clinical problems.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.